Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Athenex Inc (NQ: ATNX )

11.50 USD +0.08 (+0.70%)
Official Closing Price Updated: 7:56 PM EST, Jan 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Athenex Inc

< Previous 1 2 3 4 5 Next >
CEO Dr. Johnson Lau Contracts COVID-19
From GlobeNewswire News Releases
Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis
-- Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp 
From PR Newswire
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
From GlobeNewswire News Releases
Athenex Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer
From GlobeNewswire News Releases
Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide
From GlobeNewswire News Releases
Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
From GlobeNewswire News Releases
Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020
From GlobeNewswire News Releases
Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan
From GlobeNewswire News Releases
Athenex Oncology launches Your Guide to Facing Metastatic Breast Cancer, a first-of-its-kind self-care resource for people living with metastatic breast cancer (MBC)
Guide offers evidence-based recommendations for increasing resilience, reducing stress, maintaining proper nutrition, and other tips to facilitate managing MBC 
From PR Newswire
Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy
Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S. 
From GlobeNewswire News Releases
Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock
From GlobeNewswire News Releases
Athenex, Inc. Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2
From GlobeNewswire News Releases
Focusing On Stocks With Great Upside In Past 5 days: $KCAC $TCON $ATNX
Tags The Market Signal
From The Market Signal
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review
From GlobeNewswire News Releases
Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Athenex Announces $50 Million Revenue Interest Financing with Sagard Healthcare Royalty Partners
From GlobeNewswire News Releases
Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors
Pharmaceutical industry veteran with significant oncology clinical development expertise appointed to Board 
From GlobeNewswire News Releases
Athenex, Inc. to Report Second Quarter 2020 Earnings Results on August 6, 2020
From GlobeNewswire News Releases
CORRECTION-New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Athenex Appoints Teresa Bair, Esq. as Executive Officer and General Counsel
From GlobeNewswire News Releases
Athenex Announces $225 Million Loan Agreement with Oaktree
From GlobeNewswire News Releases
Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer
Campaign features stories of hope, tears, and encouragement from a diverse group of 9 individuals with metastatic breast cancer [MBC] 
From PR Newswire
NASDAQ:ATNX Investor Notice: Investigation over Possible Securities Laws Violations by Athenex, Inc.
San Diego, CA -- (SBWIRE) -- 06/09/2020 -- An investigation was announced over potential securities laws violations by Athenex, Inc. in connection with certain financial statements. 
From SBWire - Latest Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.